Background: The magnitude of protection conferred following recovery from COVID-19 or by vaccine administration, and the duration of protective immunity developed, remains ambiguous. Methods: We investigated the factors associated with anti-SARS-CoV-2 S1 IgG decay in 519 individuals who recovered from COVID-19 illness or received COVID-19 vaccination with two commercial vaccines, viz., an adenoviral vector-based (AZD1222) and a whole-virion-based inactivated (BBV152) vaccine in Chennai, India from March to December 2021. Blood samples collected during regular follow-up post-infection/-vaccination were examined for anti-SARS-CoV-2 S1 IgG by a commercial automated chemiluminescent immunoassay (CLIA). Results: Age and underlying comorbidities were the two variables that were independently associated with the development of a breakthrough infection. Individuals who were >60 years of age with underlying comorbid conditions (viz., hypertension, diabetes mellitus and cardiovascular disease) had a ~15 times and ~10 times greater odds for developing a breakthrough infection and hospitalization, respectively. The time elapsed since the first booster dose was associated with attrition in anti-SARS-CoV-2 IgG, where each month passed was associated with an ebb in the anti-SARS-CoV-2 IgG antibody levels by a coefficient of -6 units. Conclusions: Our findings advocate that the elderly with underlying comorbidities be administered with appropriate number of booster doses with AZD1222 and BBV152 against COVID-19.
Background: The magnitude of protection conferred following recovery from COVID-19 or by vaccine administration, and the duration of protective immunity developed, remains ambiguous. Methods: We investigated the factors associated with anti-SARS-CoV-2 S1 IgG decay in 519 individuals who recovered from COVID-19 illness or received COVID-19 vaccination with two commercial vaccines, viz., an adenoviral vector-based (AZD1222) and a whole-virion-based inactivated (BBV152) vaccine in Chennai, India from March to December 2021. Blood samples collected during regular follow-up post-infection/-vaccination were examined for anti-SARS-CoV-2 S1 IgG by a commercial automated chemiluminescent immunoassay (CLIA). Results: Age and underlying comorbidities were the two variables that were independently associated with the development of a breakthrough infection. Individuals who were >60 years of age with underlying comorbid conditions (viz., hypertension, diabetes mellitus and cardiovascular disease) had a ~15 times and ~10 times greater odds for developing a breakthrough infection and hospitalization, respectively. The time elapsed since the first booster dose was associated with attrition in anti-SARS-CoV-2 IgG, where each month passed was associated with an ebb in the anti-SARS-CoV-2 IgG antibody levels by a coefficient of -6 units. Conclusions: Our findings advocate that the elderly with underlying comorbidities be administered with appropriate number of booster doses with AZD1222 and BBV152 against COVID-19.
Authors: Nina Le Bert; Anthony T Tan; Kamini Kunasegaran; Christine Y L Tham; Morteza Hafezi; Adeline Chia; Melissa Hui Yen Chng; Meiyin Lin; Nicole Tan; Martin Linster; Wan Ni Chia; Mark I-Cheng Chen; Lin-Fa Wang; Eng Eong Ooi; Shirin Kalimuddin; Paul Anantharajah Tambyah; Jenny Guek-Hong Low; Yee-Joo Tan; Antonio Bertoletti Journal: Nature Date: 2020-07-15 Impact factor: 49.962
Authors: Nicole Doria-Rose; Mehul S Suthar; Mat Makowski; Sarah O'Connell; Adrian B McDermott; Britta Flach; Julie E Ledgerwood; John R Mascola; Barney S Graham; Bob C Lin; Sijy O'Dell; Stephen D Schmidt; Alicia T Widge; Venkata-Viswanadh Edara; Evan J Anderson; Lilin Lai; Katharine Floyd; Nadine G Rouphael; Veronika Zarnitsyna; Paul C Roberts; Mamodikoe Makhene; Wendy Buchanan; Catherine J Luke; John H Beigel; Lisa A Jackson; Kathleen M Neuzil; Hamilton Bennett; Brett Leav; Jim Albert; Pratap Kunwar Journal: N Engl J Med Date: 2021-04-06 Impact factor: 91.245
Authors: David S Khoury; Deborah Cromer; Arnold Reynaldi; Timothy E Schlub; Adam K Wheatley; Jennifer A Juno; Kanta Subbarao; Stephen J Kent; James A Triccas; Miles P Davenport Journal: Nat Med Date: 2021-05-17 Impact factor: 87.241
Authors: Marisa Stebegg; Saumya D Kumar; Alyssa Silva-Cayetano; Valter R Fonseca; Michelle A Linterman; Luis Graca Journal: Front Immunol Date: 2018-10-25 Impact factor: 7.561
Authors: Daniel F Gudbjartsson; Gudmundur L Norddahl; Pall Melsted; Kristbjorg Gunnarsdottir; Hilma Holm; Elias Eythorsson; Asgeir O Arnthorsson; Dadi Helgason; Kristbjorg Bjarnadottir; Ragnar F Ingvarsson; Brynja Thorsteinsdottir; Steinunn Kristjansdottir; Kolbrun Birgisdottir; Anna M Kristinsdottir; Martin I Sigurdsson; Gudny A Arnadottir; Erna V Ivarsdottir; Margret Andresdottir; Frosti Jonsson; Arna B Agustsdottir; Jonas Berglund; Berglind Eiriksdottir; Run Fridriksdottir; Elisabet E Gardarsdottir; Magnus Gottfredsson; Olafia S Gretarsdottir; Steinunn Gudmundsdottir; Kjartan R Gudmundsson; Thora R Gunnarsdottir; Arnaldur Gylfason; Agnar Helgason; Brynjar O Jensson; Aslaug Jonasdottir; Hakon Jonsson; Thordur Kristjansson; Karl G Kristinsson; Droplaug N Magnusdottir; Olafur T Magnusson; Lovisa B Olafsdottir; Solvi Rognvaldsson; Louise le Roux; Gudrun Sigmundsdottir; Asgeir Sigurdsson; Gardar Sveinbjornsson; Kristin E Sveinsdottir; Maney Sveinsdottir; Emil A Thorarensen; Bjarni Thorbjornsson; Marianna Thordardottir; Jona Saemundsdottir; S Hjortur Kristjansson; Kamilla S Josefsdottir; Gisli Masson; Gudmundur Georgsson; Mar Kristjansson; Alma Moller; Runolfur Palsson; Thorolfur Gudnason; Unnur Thorsteinsdottir; Ingileif Jonsdottir; Patrick Sulem; Kari Stefansson Journal: N Engl J Med Date: 2020-09-01 Impact factor: 91.245